BioRegenx, Inc.
BRGX
$0.0129
$0.001917.27%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -182.76% | -196.49% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -182.76% | -196.49% | -- | -- | -- |
| Cost of Revenue | -150.63% | -123.41% | -- | -- | -- |
| Gross Profit | -196.89% | -228.38% | -- | -- | -- |
| SG&A Expenses | -46.08% | 1,496.60% | -- | -- | -- |
| Depreciation & Amortization | 27,491.53% | 17,964.41% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.78% | 1,012.47% | -- | -- | -- |
| Operating Income | -96.91% | -3,179.86% | -- | -- | -- |
| Income Before Tax | -142.09% | -2,094.46% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -142.09% | -2,094.46% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -142.09% | -2,094.46% | -- | -- | -- |
| EBIT | -96.91% | -3,179.86% | -- | -- | -- |
| EBITDA | -9.26% | -2,550.72% | -- | -- | -- |
| EPS Basic | -22.22% | 29.57% | -- | -- | -- |
| Normalized Basic EPS | -13.64% | 34.72% | -- | -- | -- |
| EPS Diluted | -22.22% | 29.57% | -- | -- | -- |
| Normalized Diluted EPS | -13.64% | 34.72% | -- | -- | -- |
| Average Basic Shares Outstanding | 29.99% | 47.75% | -- | -- | -- |
| Average Diluted Shares Outstanding | 29.99% | 47.75% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
